Vicarious Surgical (RBOT) Form 144 — 239 Shares Proposed Sale via UBS
Rhea-AI Filing Summary
Vicarious Surgical Inc. (RBOT) Form 144 shows a proposed sale of 239 shares of Class A common stock through UBS Financial Services with an aggregate market value of $1,386 and an approximate sale date of 09/03/2025 on the NYSE. The filing reports the securities were acquired on 09/02/2025 via a restricted stock lapse from Vicarious Surgical Inc. and indicates 696 shares were acquired in that transaction.
The filing also discloses three prior sales by the listed seller, Sammy Khalifa, during the past three months: 239 shares on 06/03/2025 for $1,641, 223 shares on 06/23/2025 for $1,650, and 653 shares on 08/20/2025 for $3,801. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information about the issuer.
Positive
- Contains specific proposed sale details: 239 Class A shares with aggregate market value $1,386
- Discloses acquisition source and date: 696 shares acquired via restricted stock lapse on 09/02/2025
- Lists recent prior sales with dates and gross proceeds for transparency (06/03/2025, 06/23/2025, 08/20/2025)
Negative
- Filer identification fields (CIK/CCC and submission contact) appear blank or not provided in the content
- The filing contains no issuer financial results or operational details—only transactional disclosure
Insights
TL;DR: Routine Form 144 filing disclosing a small proposed sale and recent prior sales; no new operational or financial disclosure.
The filing documents a proposed sale of 239 Class A shares through UBS with specific acquisition details (restricted stock lapse on 09/02/2025) and lists three prior sales by the named seller with gross proceeds. From a market-disclosure perspective this is a routine insider/affiliate notice required under Rule 144 and contains transactional detail but no operational results, guidance, or new issuer-specific financial metrics. The filing helps maintain transparency about insider selling activity but does not itself convey material corporate developments.
TL;DR: Disclosure meets procedural requirements; includes representation regarding undisclosed material information.
The form includes the required representation that the selling person is unaware of undisclosed material adverse information and documents the acquisition source (restricted stock lapse) and broker. Contact and filer identifier fields in the filing appear blank in the provided content, while the seller name and prior sales are listed. This filing appears procedural and consistent with Rule 144 notice obligations rather than signaling governance or control changes.